A5102959933- Thyroid Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Cardiovascular Health and Disease Prevention
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Treatments and Mutations
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Spine and Intervertebral Disc Pathology
- Spinal Fractures and Fixation Techniques
- Ferroptosis and cancer prognosis
- Metastasis and carcinoma case studies
- Head and Neck Cancer Studies
- Cervical and Thoracic Myelopathy
- Neuroblastoma Research and Treatments
- Gastrointestinal Tumor Research and Treatment
- Cancer, Lipids, and Metabolism
Huazhong University of Science and Technology
2024
Central Hospital of Wuhan
2024
Tianjin Medical University General Hospital
2023
Hospital Tuanku Ja’afar
2022
University of Pittsburgh
2019
The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.This multicenter, double-blind, placebo-controlled, III enrolled 191 RAIR-DTC randomized a ratio 2:1 (300 mg twice daily,...
Objective Nasopharyngeal carcinoma (NPC) patients frequently present with distant metastasis (DM), which is typically associated poor prognosis. This study aims to develop and apply machine learning models predict DM, overall survival (OS), cancer-specific (CSS) in NPC provide optimal tools for improved predictive accuracy performance. Methods We retrieved over 8,000 patient samples clinical information from the Surveillance, Epidemiology, End Results (SEER) database. Utilizing two methods...
Focal cervical kyphotic deformity (FCK) without neurologic compression is not uncommon in patients with spondylotic myelopathy (CSM) who underwent anterior decompression and fusion (ACDF) surgery. It remains unclear whether FCK at non-responsible levels needs to be treated simultaneously. This study aims investigate the prognostic factor for CSM elucidate surgical indication FCK.
<p>Supplementary Material</p>
<div>Abstract<p>Purpose: The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumour activity safety RAIR-DTC patients. Patients Methods: This multicenter, double-blind, placebo-controlled, III...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<p>Supplementary Figure S3. Kaplan-Meier plot of time to treatment failure</p>
<div>AbstractPurpose:<p>Lenvatinib has shown efficacy in treating radioiodine-refractory differentiated thyroid cancer (RR-DTC) the multinational phase III SELECT study; however, it not been tested Chinese patients with RR-DTC.</p>Patients and Methods:<p>Chinese confirmed RR-DTC (<i>n</i> = 151) were randomly assigned 2:1 to receive lenvatinib 24 mg/day or placebo 28-day cycles. The primary endpoint was progression-free survival, key secondary endpoints...
<p>Supplementary Figure S1. Forest plot of PFS hazard ratios for lenvatinib versus placebo (by IIR using RECIST v1.1)</p>
<p>Supplementary Figure S2. Kaplan-Meier plot of OS a (full analysis set)</p>
Objective To investigate values of serum midkine (MK) as a diagnostic biomarker in DTC before surgery, and prognostic 131I ablation therapy. Methods A total 162 patients (70 with 92 benign thyroid nodules) participated the surgical cohort, 75 healthy subjects served controls. Diagnostic pre-surgical MK Tg for were conducted by ROC curves. A 214 treatment cohort. Prognostic pre-131I-ablative to predict 131I-avid metastases performed Independent two-sample t test or Mann-Whitney u was...
<div>AbstractPurpose:<p>The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.</p>Patients Methods:<p>This multicenter, double-blind,...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<div>Abstract<p>Purpose: The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumour activity safety RAIR-DTC patients. Patients Methods: This multicenter, double-blind, placebo-controlled, III...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<div>AbstractPurpose:<p>The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.</p>Patients Methods:<p>This multicenter, double-blind,...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>